Skip to main content
. 2022 Apr 24;22:400. doi: 10.1186/s12879-022-07371-w

Table 2.

Demographics and clinical characteristics of patients with MRSA BSI with and without nasal colonization

Factor Colonized
N = 37 (%)
Not colonized
N = 16 (%)
Univariate analysis
OR (95% CI)
p value Multivariable analysis
OR (95% CI)
p value
Sex
 Male 27 (73) 7 (44) 3.47 (1.02–11.82) 0.05 5.06 (1.64–22.01) 0.03
 Female 10 (27) 9 (56) Reference Reference
Race/ethnicity
 Non-hispanic white 13 (35) 7 (44) Reference
 Non-hispanic black 11 (30) 4 (25) 1.48 (0.34–6.43) 0.60
 Hispanic/latino 11 (30) 5 (31) 1.19 (0.29–4.81) 0.81
 Asian 1 (3) 0 (0)
 Other/not reported 1 (3) 0 (0)
Age at time of infection
 18–54 years 12 (32) 2 (13) Reference
 55–69 years 16 (43) 6 (38) 0.44 (0.08–2.60) 0.37
 ≥ 70 years 9 (24) 8 (50) 0.19 (0.03–1.11) 0.06
History of IV drug use
 Yes 2 (5) 1 (6) 0.86 (0.07–10.19) 0.90
 No 35 (95) 15 (94) Reference
HIV diagnosis
 Yes 6 (16) 0 (0)
 No 31 (84) 16 (100)
Admission source
 Home 22 (59) 13 (81) Reference
 NH/Rehab/LTACH 10 (27) 2 (13) 2.96 (0.56–15.63) 0.20
Other hospital 5 (14) 1 (6) 2.96 (0.31–28.14) 0.35
Prior hospital admission (90 days)
 Yes 26 (70) 6 (38) 3.94 (1.15–13.52) 0.03 3.96 (1.01–15.56) 0.05
 No 11 (30) 10 (63) Reference Reference
Length of hospital stay prior to BSI
 CO-MRSA 20 (54) 10 (63) Reference
 HO-MRSA 17 (46) 6 (38) 1.42 (0.43–4.71) 0.57
Clonal complex
 CC8 13 (35) 9 (56) Reference
 CC5 19 (51) 5 (31) 2.63 (0.72–9.66) 0.15
 Other 5 (14) 2 (13) 1.73 (0.27–10.97) 0.56
Frequent healthcare interaction
 Hemodialysis 12 (32) 1 (6) 8.00 (0.92–69.84) 0.06
 Infusion Center 7 (19) 3 (19) 1.56 (0.33–7.24) 0.57
 None 18 (49) 12 (75) Reference
Presence of invasive device
 Yes 30 (81) 10 (63) 2.57 (0.70–9.48) 0.16
 No 7 (19) 6 (38) Reference
Invasive procedures
 Yes 13 (35) 4 (25) 1.63 (0.44–6.07) 0.47
 No 24 (65) 12 (75) Reference
Wound present
 Yes 21 (57) 6 (38) 2.19 (0.66–7.29) 0.20
 No 16 (43) 10 (63) Reference
Charlson comorbidity index (CCI)
 0–3 4 (11) 5 (31) Reference Reference
 4–5 12 (32) 4 (25) 3.75 (0.66–21.25) 0.14 7.44 (0.95–58.45) 0.06
 6–8 15 (41) 4 (25) 4.69 (0.84–26.08) 0.08 7.84 (1.03–59.84) 0.05
 > 8 6 (16) 3 (19) 2.50 (0.37–16.89) 0.35 3.68 (0.44–30.88) 0.23
History of transplant
 Yes 6 (16) 1 (6) 2.90 (0.32–26.33) 0.34
 No 31 (84) 15 (94) Reference
History of MRSA colonization
 Yes 14 (38) 2 (13) 4.26 (0.84–21.60) 0.08
 No 23 (62) 14 (88) Reference
Presumed source of MRSA BSI
 Peripheral IV 5 (14) 2 (13) 1.09 (0.19–6.33) 0.92
 Skin and soft tissue infection 7 (19) 4 (25) 0.70 (0.17–2.84) 0.62
 Pneumonia 3 (8) 1 (6) 1.32 (0.13–13.78) 0.81
 Diabetic foot infection 1 (3) 0 (0)
 Vascular access 11 (30) 3 (19) 1.83 (0.43–7.74) 0.41
 Sacral wound 2 (5) 2 (13) 0.40 (0.05–3.13) 0.38
 Other/unknown 8 (22) 4 (25) 0.83 (0.21–3.28) 0.79

See Table 1 for definitions

Bold = significant at ≤ 0.05

IV intravenous, NH nursing home, Rehab rehabilitation facility, LTACH long-term acute care hospital, CO community-onset, HO hospital-onset, MRSA methicillin-resistant Staphylococcus aureus, BSI bloodstream infection, HIV human immunodeficiency virus